8-K ·Filed Apr 10, 2026
8-K context-dependent: Items 7.01
Actionable Insight • Neutral
Monitor for clinical data in Q4 2026 that could validate DA-1726's efficacy and tolerability profile compared to existing GLP-1 therapies
Final — all horizons settled through T+60d
MTVA ▲ +12.06% at T+60d
NEUTRAL call +12.06% · α vs SPY +1.73% · entry $1.41 → $1.58
T+1d
+6.38%
call +6.38% · α +5.41%
$1.50
settled 7mo ago
T+5d
-0.71%
call -0.71% · α -5.21%
$1.40
settled 6mo ago
T+20d
-5.67%
call -5.67% · α -14.20%
$1.33
settled 6mo ago
T+60d
+12.06%
call +12.06% · α +1.73%
$1.58
settled 4mo ago
Price Chart
Loading chart...
Executive Summary
MetaVia Inc. announced the first patient dosing in Part 3 of its Phase 1 clinical trial for DA-1726, a dual GLP-1/glucagon agonist for obesity. The trial evaluates higher-dose regimens to improve efficacy and tolerability, with data expected in Q4 2026.
Key Facts
- First patient dosed in Part 3 of Phase 1 trial for DA-1726
- Part 3 evaluates one-step (48 mg) and two-step (64 mg) dose titration regimens
- Study includes 40 obese, otherwise healthy adult subjects
- Primary endpoints: safety, tolerability, adverse events
- Secondary endpoints: weight loss, waist circumference, glycemic control
- Data expected in Q4 2026
Financial Impact
No financial impact disclosed
Risk Factors
- Clinical trial may not demonstrate improved efficacy or tolerability
- Potential safety issues in higher-dose cohorts
- Competitive landscape with established GLP-1 therapies
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-041784 |
| Document: mtva-20260410xex99d1.htm | 0001104659-26-041784 |
| Document: 0001104659-26-041784-index-headers.html | 0001104659-26-041784 |
| Document: 0001104659-26-041784-index.html | 0001104659-26-041784 |
| Document: 0001104659-26-041784.txt | 0001104659-26-041784 |
13 reports for MTVA
33% Hit rate @ T+20 Went positive at some point 1 of 3 best @ T+20▲ +2.70%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 3 | $1.36 | awaiting T+20 | — | $1.22 (−10.66%) |
Oct 13, 2026 13d ago | 8-K | $1.43 | awaiting T+20 | — | $1.22 (−15.03%) |
Sep 9, 2026 6w ago | 8-K | $1.74 $1.46 | ▼ −16.09% | ▼ −18.04% | $1.22 (−30.17%) |
Jul 9, 2026 15w ago | 8-K | $1.73 $1.45 | ▼ −16.18% | ▼ −18.43% | $1.22 (−29.77%) |
Jul 2, 2026 16w ago | 424B5 | $1.48 $1.44 | ▲ +2.70% | ▲ +2.29% | $1.22 (+17.91%) |
Jun 8, 2026 20w ago | 8-K | $1.89 $1.58 | ▼ −16.40% | ▼ −17.85% | $1.22 (−35.71%) |
Jun 8, 2026 20w ago | 8-K | $2.22 $1.51 | ▼ −31.98% | ▼ −33.61% | $1.22 (−45.27%) |
May 27, 2026 21w ago | 8-K | $3.34 $1.53 | ▼ −54.19% | ▼ −52.29% | $1.22 (−63.62%) |
May 18, 2026 23w ago | 8-K | $1.11 $1.65 | ▲ +48.65% | ▲ +47.07% | $1.22 (+9.46%) |
May 14, 2026 23w ago | 8-K | $1.11 $1.71 | ▲ +54.05% | ▲ +51.94% | $1.22 (+9.46%) |
Showing 10 of 13
US Market Status
Market Closed — Opens in 5h 4m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers